Extended-release niacin with laropiprant: A review on efficacy, clinical effectiveness and safety

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 9, 2012, Pages 1345-1362

  Yadav, Rahul ^a   France, Michael ^b   Younis, Naveed ^b   Hama, Salam ^a   Ammori, Basil J ^a   Kwok, See ^a   Soran, Handrean ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clinical effectiveness; Efficacy; HDL C; Hyperlipidemia; Laropiprant; Niacin; Safety; Tredaptive

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CLOPIDOGREL; COLESTIPOL; EZETIMIBE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LAROPIPRANT PLUS NICOTINIC ACID; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN D2; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADIPOCYTE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BIBLIOGRAPHIC DATABASE; BILIRUBIN BLOOD LEVEL; BLEEDING; BRAIN ISCHEMIA; BURNING SENSATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CUTANEOUS FLUSHING; DIABETES MELLITUS; DNA REPAIR; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ELECTROCARDIOGRAM; ENDOCYTOSIS; EVIDENCE BASED MEDICINE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEMOGLOBIN A1C BLOOD LEVEL; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOLYSIS; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDICAL SOCIETY; MEDLINE; META ANALYSIS; METABOLIC SYNDROME X; MONOTHERAPY; MORBIDITY; MORTALITY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PHOSPHATE BLOOD LEVEL; PLEIOTROPY; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; FLUSHING; HUMANS; HYPOLIPIDEMIC AGENTS; INDOLES; LIPIDS; NIACIN; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84861372936     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.690395     Document Type: Review

References (131)

1. Soran H, Durrington P. Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opin Pharmacother 2008;9:2145-60
2. Shepherd J, Blauw G J, Murphy M B, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
5. Bhatnagar D, Soran H, Durrington PN. Hypercholesterolaemia and its management. BMJ 2008;337:a993
6. Whayne TF Jr. High-density lipoprotein cholesterol: current perspective for clinicians. Angiology 2009;60:644-9
7. Chapman MJ, Redfern JS, McGovern ME, et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010;126:314-45
8. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22
9. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14
10. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-13
11. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-13
12. Sacks FM. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. Am J Cardiol 2001;88:14N-8N
13. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
14. Brookes L. Studies of raising HDL cholesterol: updates European Society of Cardiology (ESC) 2008 Congress. Medscape Cardiology, Medscape Conference Coverage 2009. Available from: http://www.medscape.com/ viewarticle/585306
15. Olsson A. Short and Long Term HDL-C Effects. In XIV International Symposium on Drugs Affecting LipidMetabolism; New York, USA; 2001
16. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
17. Carlson LA, Oro L, Ostman J. Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia. Acta Med Scand 1968;183:457-65
18. Parsons WB Jr, Achor RW, Berge KG, et al. Changes in concentration of blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia: preliminary observations. Proc Staff Meet Mayo Clin 1956;31:377-90
19. Parsons WB Jr, Flinn JH. Reduction of serum cholesterol levels and beta-lipoprotein cholesterol levels by nicotinic acid. AMA Arch Intern Med 1959;103:783-90
20. The Coronary Drug Project Research Group. Clofibrate and niacin in Coronary Heart disease. J Am Med Assoc 1975;231:360-81
21. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98
22. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
23. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17
24. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50
25. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
26. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67
27. Nomura H, Nielsen BW, Matsushima K. Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. Int Immunol 1993;5:1239-49
28. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-5
29. Ganji SH, Tavintharan S, Zhu D, et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004;45:1835-45
30. Lamon-Fava S, Diffenderfer MR, Barrett PH, et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:1672-8
31. Watts GF, Chan DC. Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism. Arterioscler Thromb Vasc Biol 2008;28:1892-5
32. van der Hoorn JW, de Haan W, Berbee JF, et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE. *3Leiden. CETP mice. Arterioscler Thromb Vasc Biol 2008;28:2016-22
33. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:2020-8
34. Martinez LO, Jacquet S, Esteve JP, et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003;421:75-9
35. Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004;67:411-19
36. Choudhury RP, Lee JM, Greaves DR. Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med 2005;2:309-15
37. Pandolfi PP, Sonati F, Rivi R, et al. Targeted disruption of the housekeeping gene encoding glucose 6-phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. EMBO J 1995;14:5209-15
38. Ito Y, Pagano PJ, Tornheim K, et al. Oxidative stress increases glyceraldehyde-3-phosphate dehydrogenase mRNA levels in isolated rabbit aorta. Am J Physiol 1996;270:H81-7
39. Cao Z, Li Y. Chemical induction of cellular antioxidants affords marked protection against oxidative injury in vascular smooth muscle cells. Biochem Biophys Res Commun 2002;292:50-7
40. Jacobson EL, Jacobson MK. A biomarker for the assessment of niacin nutriture as a potential preventive factor in carcinogenesis. J Intern Med 1993;233:59-62
41. Ganji SH, Qin S, Zhang L, et al. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009;202:68-75
42. Yan Q, Briehl M, Crowley CL, et al. The NAD+ precursors, nicotinic acid and nicotinamide upregulate glyceraldehyde-3-phosphate dehydrogenase and glucose-6-phosphate dehydrogenase mRNA in Jurkat cells. Biochem Biophys Res Commun 1999;255:133-6
43. Ganji SH. Niacin inhibits LDL oxidation and redox-sensitive VCAM-1 and MCP-1 expression in human aortic endothelial cells [abstract]. Arterioscler Thromb Vasc Biol 2004;24:125
44. Digby JE, McNeill E, Dyar OJ, et al. Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis 2010;209:89-95
45. Kuvin JT, Dave DM, Sliney KA, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006;98:743-5
46. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985;34:642-50
47. Birjmohun RS, Hutten BA, Kastelein JJ, et al. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med 2004;62:229-34
48. Kamal-Bahl SJ, Burke T, Watson D, et al. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007;99:530-4
49. Kamal-Bahl SJ, Burke TA, Watson DJ, et al. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Curr Med Res Opin 2008;24:1817-21
50. Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009;104:74-81
51. Benyo Z, Gille A, Bennett CL, et al. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol 2006;70:1844-9
52. Benyo Z, Gille A, Kero J, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005;115:3634-40
53. Maciejewski-Lenoir D, Richman JG, Hakak Y, et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol 2006;126:2637-46
54. Sturino CF, O'Neill G, Lachance N, et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7- fluoro-5- (methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b]indol-3-yl]-acetic acid (MK- 0524). J Med Chem 2007;50:794-806
55. Yadav R, Kwok S, Ammori BJ, et al. Safety and tolerability of extended-release niacin with laropiprant. Expert Opin Drug Saf 2012;11:151-9
56. Lai E, Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2008;83:840-7
57. Lai E, Schwartz JI, Dallob A, et al. Effects of extended release niacin/ laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets 2010;21:191-8
58. MSD. Summary of product characteristics TREDAPTIVE 1000 mg/ 20 mg modified release tablets. 2011.Available from: http://www. medicines.org.uk/EMC/ medicine/22227/ SPC/TREDAPTIVE+1000+mg+20+mg+ modified+release+tablets/
59. Mrochek JE, Jolley RL, Young DS, et al. Metabolic response of humans to ingestion of nicotinic acid and nicotinamide. Clin Chem 1976;22:1821-7
60. Cayen MN. Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man. Pharmacol Ther 1985;29:157-204
61. McKenney JM, Proctor JD, Harris S, et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7
62. Menon RM, Gonzalez MA, Adams MH, et al. Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites. J Clin Pharmacol 2007;47:681-8
63. Knopp RH. Evaluating niacin in its various forms. Am J Cardiol 2000;86:51L-6L
64. Wang YH, Liu F, Luk JA, et al. Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment. J Clin Pharmacol 2011;51:406-12
65. Stroh M, Wenning L, Luo WL, et al. Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency. Am J Ther 2009;16:379-84
66. Dallob A, Luo WL, Luk JM, et al. The effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin. Platelets 2011;22:495-503
67. Schwartz JI, Liu F, Stroh M, et al. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin. Am J Ther 2009;16:215-23
68. Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled Trial. J Cardiovasc Pharmacol Ther 1996;1:195-202
69. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097-104
70. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-5
71. Insull W Jr, McGovern ME, Schrott H, et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: ssessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004;164:1121-7
72. Hunninghake DB, McGovern ME, Koren M, et al. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 2003;26:112-18
73. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998;82:74U-81U.discussion 5U-6U
74. Insull W Jr, Toth PP, Superko HR, et al. Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. Vasc Health Risk Manag 2010;6:1065-75
75. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-76
76. Younis NN, Soran H, Sharma R, et al. Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc Dis Res 2010;7:289-95
77. Soran H, Durrington PN. Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol 2011;22:254-61
78. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003;5(Suppl 1):S19-27
79. Morgan JM, Capuzzi DM, Baksh RI, et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003;91:1432-6
80. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003;91:667-72
81. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23
82. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53
83. Utermann G. Lipoprotein(a). In: Scriver CR, Beaudet AL, editors. The metabolic and molecular bases of inherited disease. McGraw Hill; New York: 2001. p. 2753-87
84. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 2004;15:167-74
85. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/ laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959-70
86. McGovern M. Niaspan: creating a new concept for raising HDL-cholesterol. European Heart Journal Supplements 2005;7:41-7
87. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15
88. Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med 1994;154:1106-10
89. Soma M, Fumagalli R, Paoletti R, et al. Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women. Lancet 1991;337:612
90. Canner PL, Berge KG, Wenger NK, et al. Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55
91. Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787-94
92. Brown BG, Brockenbrough A, Zhao X. Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up [abstract 3341]. Circulation 1998;98:I-635
93. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J 2011;161:471-7.e2
94. NIH stops clinical trial on combination cholesterol treatment: lack of efficacy in reducing cardiovascular events prompts decision. National Institute of Health News 2011. Available from: http://www. nih.gov/news/health/may2011/ nhlbi-26. htm
95. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(Suppl 1):S11-61
96. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007;298:786-98
97. First ESC/EAS guidelines for dyslipidemia- EAS 2011 Gothenburg, Sweden. 2011.Available from: http://www.eassociety. org/News.aspx?newsId=118 [Cited 7 January 2011]
98. NICE Clinical Guidelines, No. 66, London. 2008.Available from: http://www.ncbi. nlm.nih.gov/books/NBK53885/
99. Cooper A, O'Flynn N. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ 2008;336:1246-8
100. Bays HE, Shah A, Lin J, et al. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. J Clin Lipidol 2010;4:515-21
101. Gleim G. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol 2009;16:90-7
102. Shah S, Ceska R, Gil-Extremera B, et al. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2010;64:727-38
103. Maclean A. Efficacy and safety of extended-release niacin/laropiprant in patients with type 2 diabetes mellitus. Br J Cardiol 2011;18:37-45
104. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007;99:22C-31C
105. Tato F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol 1998;81:805-7
106. Vaccari CS, Hammoud RA, Nagamia SH, et al. Revisiting niacin: reviewing the evidence. J Clin Lipidol 2007;1:248-55
107. Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol 2003;6:179-88
108. Durrington P. Hyperlipidaemia diagnosis and management. 3rd edition. Hodder Arnold; London: 2007
109. K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. American Journal of Kidney Diseases 2003;41:Suppl 3
110. Increased myopathy with combination use of ER niacin/laropiprant (Tredaptive-) and simvastatin 40 mg in Chinese patients. Results from interim analysis of HPS2-THRIVE study. Safety alerts 2010. Available from: http://www. hsa.gov.sg/publish/hsaportal/en/ health-products-regulation/ safety-information/product-safety-alerts/ safety-alerts-2010/increased-myopathy. html
111. Carlson LA. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand 1963;173:719-22
112. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106:171-6
113. Durrington PN. Hyperlipidaemia: diagnosis and management. Hodder Arnold; London: 2007
114. Schwartz ML. Severe reversible hyperglycemia as a consequence of niacin therapy. Arch Intern Med 1993;153:2050-2
115. McCulloch DK, Kahn SE, Schwartz MW, et al. Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons. J Clin Invest 1991;87:1395-401
116. Canner PL, Furberg CD, Terrin ML, et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005;95:254-7
117. Sampathkumar K, Selvam M, Sooraj YS, et al. Extended release nicotinic acid - a novel oral agent for phosphate control. Int Urol Nephrol 2006;38:171-4
118. Takahashi Y, Tanaka A, Nakamura T, et al. Nicotinamide suppresseshyperphosphatemia in hemodialysis patients. Kidney Int 2004;65:1099-104
119. Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-97
120. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008;101:625-30
121. McKenney J. Safety profile of extended release niacin/laropiprant in patients with dyslipidemia. J Am Coll Cardiol 2008;51:334
122. Lauring B, Dishy V, Luo WL, et al. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. J Clin Pharmacol 2009;49:1426-35
123. Dishy V, Liu F, Ebel DL, et al. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol 2009;49:416-22
124. Soran H, France MW, Kwok S, et al. Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients. Ann Clin Biochem 2011;48:566-71
125. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
126. Tonkin AM, Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122:850-2
127. Mymin D, Dembinski T, Friesen MH. Iatrogenic severe depression of high-density lipoprotein cholesterol. J Clin Pharmacol 2009;49:865-71
128. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal- PLAQUE): a randomised clinical trial. Lancet 2011;378:1547-59
129. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306:2099-109
130. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40
131. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12